Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 1/20 | 0.42 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.42 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.42 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 9/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 3/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.37 |
| ▸ | DRD5 | P21918 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3851762 | 0.90 | SLC6A1 (0.39) | SLC6A1SLC6A12SLC6A11SLC6A13DRD2 | |
| SCHEMBL3853364 | 0.88 | DRD2 (0.45) | SLC6A1SLC6A12SLC6A11SLC6A13DRD2 | |
| SCHEMBL2782539 | 0.83 | CCR1 (0.43) | SLC6A1SLC6A12SLC6A11SLC6A13DRD2 | |
| SCHEMBL3772152 | 0.82 | DRD2 (0.46) | SLC6A1SLC6A12SLC6A11SLC6A13DRD2 | |
| SCHEMBL5500292 | 0.80 | CCR1 (0.41) | SLC6A1SLC6A12SLC6A11SLC6A13DRD2 | |
| SCHEMBL3850825 | 0.80 | DRD2 (0.50) | DRD2OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL3850817 | 0.78 | DRD2 (0.42) | SLC6A1SLC6A12SLC6A11SLC6A13DRD2 | |
| SCHEMBL2783423 | 0.78 | LMNA (0.44) | DRD2OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL3853201 | 0.77 | SSTR5 (0.44) | DRD2OPRM1OPRL1DRD3HTR1A | |
| SCHEMBL2783401 | 0.76 | DRD2 (0.57) | DRD2DRD3HTR1ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765779-B1 | NEW SUBSTITUTED PIPERIDINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | NSAB AF NEUROSEARCH SWEDEN AB (DK) | 2009-11-18 | — | — | EP | disclosed |
| US-7579474-B2 | Substituted piperidines as modulators of dopamine neurotransmission | NSAB, FILIAL AF NEUROSEARCH AB, SVERIGE (DK) | 2009-08-25 | — | — | US | disclosed |
| US-20070270467-A1 | SUBSTITUTED PIPERIDINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2007-11-22 | — | — | US | disclosed |
| EP-1765779-A1 | NEW SUBSTITUTED PIPERIDINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | A. CARLSSON RESEARCH AB (SE) | 2007-03-28 | — | — | EP | disclosed |
| WO-2005121092-A1 | NEW SUBSTITUTED PIPERIDINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | A. CARLSSON RESEARCH AB (SE) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270467-A1 | SUBSTITUTED PIPERIDINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | DRD2, PRLHR, DRD3 | SLC6A1 114/4885SLC6A12 1544/4885SLC6A11 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.